The Journal of Urology
Volume 177, Issue 6 , Pages 2141-2145 , June 2007

A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients With Androgen Independent Prostate Cancer

  • Michael Krainer

      Affiliations

    • Department of Internal Medicine I, Division of Oncology and Cancer Center, Medical University of Vienna, Vienna, Austria
    • Corresponding Author InformationCorrespondence: Department of Medicine I and Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria (telephone: +43-1-40400-4449; FAX: +43-1-40400-4451).
    • ,
  • Sandra Tomek

      Affiliations

    • Department of Internal Medicine I, Division of Oncology and Cancer Center, Medical University of Vienna, Vienna, Austria
    • ,
  • Katarzyna Elandt

      Affiliations

    • Department of Internal Medicine I, Division of Oncology and Cancer Center, Medical University of Vienna, Vienna, Austria
    • ,
  • Peter Horak

      Affiliations

    • Department of Internal Medicine I, Division of Oncology and Cancer Center, Medical University of Vienna, Vienna, Austria
    • ,
  • Walter Albrecht

      Affiliations

    • Department of Urology, Rudolfstiftung Hospital, Vienna, Austria
    • ,
  • Michael Eisenmenger

      Affiliations

    • Department of Internal Medicine I, Division of Oncology and Cancer Center, Medical University of Vienna, Vienna, Austria
    • ,
  • Wolfgang Höltl

      Affiliations

    • Department of Urology, Kaiser-Franz-Josef Hospital, Vienna, Austria
    • ,
  • Paul Schramek

      Affiliations

    • Department of Urology, Barmherzige Bruder Hospital, Vienna, Austria
    • ,
  • Walter Stackl

      Affiliations

    • Department of Urology, Rudolfstiftung Hospital, Vienna, Austria
    • ,
  • Christoph Zielinski

      Affiliations

    • Department of Internal Medicine I, Division of Oncology and Cancer Center, Medical University of Vienna, Vienna, Austria
    • ,
  • Jochen Reibenwein

      Affiliations

    • Department of Internal Medicine I, Division of Oncology and Cancer Center, Medical University of Vienna, Vienna, Austria

Received 10 November 2006

References 

  1. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999;26:14
  2. Friedland D, Cohen J, Miller R, Voloshin M, Gluckman R, Lembersky B, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 1999;26:19
  3. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273
  4. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001;28:8
  5. Gravis G, Bladou F, Salem N, Macquart-Moulin G, Serment G, Camerlo J, et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer. 2003;98:1627
  6. Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology. 2004;66:281
  7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502
  8. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513
  9. Fields-Jones S, Koletsky A, Wilding G, O’Rourke M, O’Rourke T, Eckardt J, et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol. 1999;10:1307
  10. Oudard S, Caty A, Humblet Y, Beauduin M, Suc E, Piccart M, et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol. 2001;12:847
  11. Morant R, Hsu Schmitz SF, Bernhard J, Thurlimann B, Borner M, Wernli M, et al. Vinorelbine in androgen-independent metastatic prostatic carcinoma–a phase II study. Eur J Cancer. 2002;38:1626
  12. Robles C, Furst AJ, Sriratana P, Lai S, Chua L, Donnelly E, et al. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. Oncol Rep. 2003;10:885
  13. Tralongo P, Bollina R, Aiello R, Di MA, Moruzzi G, Beretta G, et al. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer (A phase II study). Tumori. 2003;89:26
  14. Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol. 2004;15:1613
  15. Carles J, Domenech M, Gelabert-Mas A, Nogue M, Tabernero JM, Arcusa A, et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol. 1998;37:187
  16. Smith MR, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T, et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Cancer. 2000;89:1824
  17. Sweeney CJ, Monaco FJ, Jung SH, Wasielewski MJ, Picus J, Ansari RH, et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol. 2002;13:435
  18. Borrega P, Velasco A, Bolanos M, del Mar PM, Mel JR, Reina JJ, et al. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. Urol Oncol. 2004;22:32
  19. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756
  20. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506

PII: S0022-5347(07)00286-8

doi: 10.1016/j.juro.2007.01.148

The Journal of Urology
Volume 177, Issue 6 , Pages 2141-2145 , June 2007

Article Tools

* Image Usage & Resolution